The safety and efficacy, including clinically relevant reduction of morning stiffness, of low-dose DR-prednisone
in patients with active RA receiving DMARD therapy have been demonstrated versus conventional immediate-release (IR) prednisone
in the Circadian Administration of Prednisone
in Rheumatoid Arthritis (CAPRA-1) trial (27,28) and versus placebo in the CAPRA-2 trial.
Adverse events were more common with prednisone
, the most common being insomnia, increased appetite, and nervousness.
FDA based its approval of ZYTIGA plus prednisone
for treating men with mCRPC prior to chemotherapy on the results from a planned second interim analysis of COU-AA-302, which is an international, randomized, double-blind, placebo controlled Phase 3 study that included 1,088 men with mCRPC who had not received prior chemotherapy, and were randomized 1:1 to receive ZYTIGA[sup.
In 2006, the US Food and Drug Administration (FDA) approved VELCADE for the treatment of patients with MCL who have received at least one prior therapy, with a subsequent frontline treatment approval in October 2014 for VELCADE in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone
My patient is a 62-year-old pleasant woman who has been on prednisone
at high dosages for years for her polymyalgia rheumatica.
In April 2011 abiraterone acetate was approved in the US by the Food and Drug Administration (FDA)for use in combination with prednisone
or prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.
was tapered off while cyclophosphamide was continued for a total of 10 months.
For the study, researchers recruited 20 mature asthmatic patients (56 - 58 years of age) who had been taking about 10 milligrams of prednisone
for approximately nine years, along with other available asthma medication.
Although neurosarcoidosis was felt to be the diagnosis, clinical and cerebral imaging showed progression of disease on prednisone
and methotrexate therapy.
The treatment of choice is chemotherapy, which usually includes cyclophosphamide, vincristine, and prednisone
Fifty patients were randomized to evaluate the use of satraplatin plus prednisone
(n=27) versus prednisone
alone (n=23) for use as a first-line chemotherapy treatment in HRPC.
Phase II Trial of tesmilifene plus mixantrone and prednisone